Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 08 apr 2015 - 07:23
- Statutory name argenx SE
- Title arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers
- Comments Breda, The Netherlands / Ghent, Belgium, 8 April - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has advanced ARGX-111, a best-in-class highly differentiated SIMPLE Antibody(TM) targeting c-MET driven malignancies, into the safety and efficacy expansion part of its Phase 1b study. The objective of the expansion cohort is to further characterize the safety of ARGX-111 in cancer patients with MET amplified tumors, and to evaluate efficacy signals in order to select the indications to be studied in Phase 2 clinical development.
Date last update: 06 October 2022